Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
HYMB vs XBI: how they differ
HYMB and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
State Street(R) SPDR Nuveen ICE High Yield Municipal Bond ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, HYMB and XBI hold 0% of their money in the same securities at the same weight.
| Only in HYMB | Only in XBI |
|---|---|
| Puerto Rico Sales Tax Financing Corp Sal 2.53% | Apogee Therapeutics Inc 1.49% |
| Puerto Rico Sales Tax Financing Corp Sal 1.54% | Moderna Inc 1.41% |
| Buckeye Tobacco Settlement Financing Aut 1.27% | Twist Bioscience Corp 1.41% |
| Commonwealth of Puerto Rico 0.64% | Oruka Therapeutics Inc 1.38% |
| Puerto Rico Sales Tax Financing Corp Sal 0.62% | Kymera Therapeutics Inc 1.36% |
| Commonwealth of Puerto Rico 0.55% | Viking Therapeutics Inc 1.31% |
| New York Liberty Development Corp 0.47% | Praxis Precision Medicines Inc 1.29% |
| Metropolitan Pier & Exposition Authority 0.43% | Erasca Inc 1.27% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| HYMB State Street(R) SPDR Nuveen ICE High Yield Municipal Bond ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | State Street | State Street |
| What it is | SPDR Nuveen ICE High Yield Municipal Bond | SPDR S&P Biotech |
| Total return, 1 year | +1.7% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −15.8 pts | +46.5 pts |
| Expense ratio | 0.35% | 0.35% |
| Holdings | 1867 | 150 |
HYMB in plain words
HYMB is a bond fund tracking the SPDR Nuveen ICE High Yield Municipal Bond. Over the year to Sep 11, 2026 it returned +1.7% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. It sat 3.8% below its high of Jul 2, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, HYMB or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, HYMB returned +1.7% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, HYMB or XBI?
- HYMB charges 0.35% a year and XBI charges 0.35%, so HYMB is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, HYMB against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/HYMB-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources